Carfilzomib information

Carfilzomib
Clinical data
Trade names	Kyprolis
Other names	PX-171-007
AHFS/Drugs.com	Monograph
MedlinePlus	a612031
License data	US DailyMed: Carfilzomib;
Pregnancy; category	AU: C; ;
Routes of; administration	Intravenous
ATC code	L01XG02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	97%
Metabolism	Extensive; CYP plays a minor role
Identifiers
	IUPAC name (2S)-4-Methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide;
CAS Number	868540-17-4;
PubChem CID	11556711;
IUPHAR/BPS	7420;
DrugBank	DB08889;
ChemSpider	9731489;
UNII	72X6E3J5AR;
KEGG	D08880;
ChEBI	CHEBI:65347;
ChEMBL	ChEMBL451887;
CompTox Dashboard (EPA)	DTXSID4048690 ;
ECHA InfoCard	100.219.957
Chemical and physical data
Formula	C40H57N5O7
Molar mass	719.924 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(OC1)C)CC(C)C)Cc2ccccc2)CC(C)C)CCc3ccccc3)CN4CCOCC4;
	InChI InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1; Key:BLMPQMFVWMYDKT-NZTKNTHTSA-N;

Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.^[4] It was developed by Onyx Pharmaceuticals.

The US Food and Drug Administration (FDA) approved it in July 2012.^[5]^[6]

^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ ^a ^b "Kyprolis- carfilzomib injection, powder, lyophilized, for solution". DailyMed. 26 August 2020. Retrieved 13 November 2020.
^ "NCI Drug Dictionary". National Cancer Institute. Retrieved 13 November 2020.
^ "FDA Approves Kyprolis for Some Patients with Multiple Myeloma". FDA. 2012-07-20. Archived from the original on 2013-01-28. Retrieved 2013-07-23.
^ "Drug Approval Package: Kyprolis (carfilzomib) for Injection NDA #202714". U.S. Food and Drug Administration (FDA). 20 August 2012. Retrieved 10 April 2023.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[2] "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

[Kyprolis_FDA_label-3] "Kyprolis- carfilzomib injection, powder, lyophilized, for solution". DailyMed. 26 August 2020. Retrieved 13 November 2020.

[dd-4] "NCI Drug Dictionary". National Cancer Institute. Retrieved 13 November 2020.

[FDA_PR_20120720-5] "FDA Approves Kyprolis for Some Patients with Multiple Myeloma". FDA. 2012-07-20. Archived from the original on 2013-01-28. Retrieved 2013-07-23.

[6] "Drug Approval Package: Kyprolis (carfilzomib) for Injection NDA #202714". U.S. Food and Drug Administration (FDA). 20 August 2012. Retrieved 10 April 2023.

Carfilzomib information

and 26 Related for: Carfilzomib information

Carfilzomib

Multiple myeloma

Diverted total synthesis

Proteolix

Epoxomicin

Onyx Pharmaceuticals

Tretinoin

Methotrexate

Isatuximab

Hydroxycarbamide

Celecoxib

Plasma cell leukemia

Fluorouracil

Gemcitabine

Vincristine

Bortezomib

Oxaliplatin

Doxorubicin

Amgen

Exatecan

Aminolevulinic acid

Lisocabtagene maraleucel

Bleomycin

Carboplatin

Antimetabolite

Venetoclax